Neuropsychiatric Drug Development
Surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape. Capitalising on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returns as the industry’s premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.
Surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape. Capitalising on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returns as the industry’s premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.
We are sponsors at this event!
Come and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, high-content imaging applications and cell therapies.
Timothy Smith, Associate Director of Sales - North America will talk on 'Leveraging CNS toolkit to build complex models' . More details to follow.
Arrange a meeting